doi:10.1038/nm.3128 145
S., Shamblin S
Product (Drug Class/Brand) Type 2 Diabetes (T2DM Byetta (exenatide) Victoza (liraglutide) Bydureon BCise (exenatide) Trulicity (dulaglutide) Adlyxin / Lyxumia (lixisenatide) Soliqua (lixisenatide/insulin glargine) FDC Xultophy / iDegLira (liraglutide / insulin degludec) FDC Ozempic (semaglutide) Rybelsus (semaglutide) Mounjaro (tirzepatide) Obesity & Weight Loss Management Saxenda (liraglutide) Wegovy (semaglutide) Zepbound (tirzepatide) Route of Administration Subcutaneous Oral Pipeline Analysis Geography North America (U.S., Canada) Latin America (Brazil, Mexico, Rest of LA) Europe (U.K., Germany, France, Italy, Spain, Rest of EU) Asia Pacific (Japan, China, India, Rest of APAC Rest of the World Company Profiles AstraZeneca plc Eli Lilly and Company Novo Nordisk A/S Sanofi S.A
however, mucosa-colored and white lesions are occasionally noted, and erythema is observed when the lesions are inflamed
Your body's tolerance and appetite-suppression response may feel reset after illness, which is normal
The results suggested that tirzepatide (Mounjaro) led to slightly higher average weight loss and greater reductions in A1C levels compared to semaglutide (Ozempic)
